Dekel Gelbman, CEO of FDNA, on "Next-Generation Phenotyping"

For the inaugural episode of Artificial Intelligence in Drug Discovery, I spoke with Dekel Gelbman, CEO of FDNA ( https://www.fdna.com/ ). FDNA enables precision medicine by using artificial intelligence for next-generation phenotyping. Their technology links genetic traits with phenotypic characteristics such as facial structure. Listen now to learn what inspired the technology, the problems it solves, how it can help in the drug discovery process, and where FDNA plans to take it. This episode is brought to you by BenchSci ( https://www.benchsci.com ). BenchSci uses artificial intelligence to reduce the cost of scientific experiments. Use it to find research antibodies up to 24x faster than using PubMed or Google Scholar. Just enter a protein of interest and filter by technique, organism, tissue, or 12 other options. BenchSci returns only relevant published figures and products. It’s free for academic researchers. Work in industry? Request a demo at https://www.benchsci.com.

Om Podcasten

Get knowledge and inspiration to apply artificial intelligence to drug development. Discover startups applying machine learning to biomedical research. Hear how biotech and pharma companies use AI to speed discovery and cut costs. Learn from academic researchers pushing boundaries in applying computation to biology. We interview leaders transforming drug development with data and algorithms. Subscribe now and never miss an episode!